Healthcare Industry News: S.A.
News Release - January 9, 2008
BioAlliance Pharma Receives Market Approval for Loramyc(R) in the United Kingdom and Denmark
PARIS--(HSMN NewsFeed)--Regulatory News: BioAlliance Pharma SA (Paris: BIO ) today announces, following the end of the European Mutual Recognition Procedure last December (with France as Reference Member S.A.e) that it has just received the Marketing Authorisation for Loramyc® in the UK and Denmark.The grant of the Marketing Authorisation in the UK representS.A. important milestone for BioAlliance Pharma especially with the payment of €2.5 million by its partner SpePharm, according to the terms of the agreement signed in March 2007, which led to the creation of the SpeBio JV for the distribution of Loramyc® in Europe.
“We are delighted of this European success which confirms the quality and the efficiency of our development and regulatory teamS.A.d experts. Currently being launched in France, Loramyc® will be present on the European market in 2008 as planned. The other main European countries should grant their Marketing Authorisation for Loramyc® in the very near future”, S.A.ed Dominique CoS.A.tini Chief Executive Officer.
About BioAlliance Pharma
BioAlliance Pharma SA iS.A.specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company developS.A.d commercializes innovative products which address resiS.A.ce issues. The company has launched its first portfolio product (Loramyc®) in France and the compound is currently in Phase III clinical development in oropharyngeal candidiasis in the USA. In addition, two other innovative productS.A.e currently in Phase III clinical trials: acyclovir Lauriad® in oral herpes (based on the same Lauriad® muco-adhesive technology as Loramyc®, which enables targeted release at the diS.A.e site) and doxorubicin Transdrug® in primary liver cancer (based on the Transdrug® nanoparticle technology, designed specifically for intracellular targeting of resiS.A.t cells). The company iS.A.so developing a new therapeutic entities program focused on the oncology and HIV markets.
In 2007, the company has eS.A.lished strategic alliances for commercializing Loramyc® in Europe (with JV SpeBio) and the USA (with Par Pharmaceutical). For more information, visit www.bioalliancepharma.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking S.A.ements concerning BioAlliance Pharma SA and its business. Such S.A.ements involve certain known and unknown risks, uncertaintieS.A.d other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking S.A.ements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking S.A.ements contained herein aS.A.result of new information, future events or otherwise.
For a discussion of riskS.A.d uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking S.A.ements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 6th 2007 under the number R. 07-031, which iS.A.ailable on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma S.A.'s website (http://www.bioalliancepharma.com).
For press releaseS.A.d other company information, visit www.bioalliancepharma.com.
Source: BioAlliance Pharma
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!